Skip to main content
Top
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Survival analysis of patients with invasive extramammary Paget disease: implications of anatomic sites

Authors: Haijun Yao, Minkai Xie, Shibo Fu, Jianhua Guo, Yubing Peng, Zhikang Cai, Yueqing Jiang, Dachao Zheng, Zhong Wang

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Extramammary Paget disease (EMPD) is a rare malignant dermatosis with poorly defined outcomes. We investigated clinical characteristics of invasive EMPD at different anatomic sites and by subject demographics to determine prognostic factors for overall survival (OS).

Methods

All patient data were collected from the Surveillance, Epidemiology, and End Results (SEER) program, 1973–2013, of the U.S. National Cancer Institute. Patients with invasive EMPD of skin, vulva/labia, vagina, scrotum/penis, or other sites were included. After excluding patients with unknown radiation status, data of 2001 patients were analyzed. Primary endpoint was EMPD mortality by anatomic sites. Independent variables included patients’ demographic data, concurrent malignancy (ie, non-EMPD related cancers), tumor size, distant metastasis, and surgery and/or radiation or not.

Results

Multivariate regression analysis showed that mortality was significantly higher in patients with vaginal EMPD than in patients with vulvar/labial EMPD (adjusted hazard ratio [aHR] = 3.26, p < 0.001). Patients with distant metastasis had higher mortality than those without (aHR = 3.36, p < 0.001). Patients who received surgery had significantly lower mortality than those who did not receive surgery (aHR = 0.77, p = 0.030), and those treated with radiation had significantly higher mortality than those who did not receive radiation (aHR = 1.60, p = 0.002). Older age was associated with significantly increased mortality (aHR = 1.09, p < 0.001), and mortality was significantly higher in males than in females (aHR = 1.42, p = 0.008).

Conclusions

In conclusion, among EMPD patients, mortality is higher in patients with vaginal EMPD than in those with vulvar/labial EMPD and higher in those who are older, those with concurrent malignancy or distant metastasis. Mortality is also higher in males than in females. Surgery is a protective factor and radiation is a risk factor for OS. Greater understanding of EMPD clinical characteristics, and considering EMPD in differential diagnosis of chronic genital and perianal dermatoses may provide support for early EMPD diagnosis and definitive surgical treatment.
Literature
1.
go back to reference Chanda JJ. Extrammammary Paget’s disease: prognosis and relationship to internal malignancy. J Am Acad Dermatol. 1985;13:1009–14.CrossRefPubMed Chanda JJ. Extrammammary Paget’s disease: prognosis and relationship to internal malignancy. J Am Acad Dermatol. 1985;13:1009–14.CrossRefPubMed
2.
go back to reference Lopes Filho LL, Lopes IM, Lopes LR, Enokihara MM, Michalany AO, Matsunaga N. Mammary and extramammary Paget’s disease. An Bras Dermatol. 2015;90:225–31.CrossRefPubMed Lopes Filho LL, Lopes IM, Lopes LR, Enokihara MM, Michalany AO, Matsunaga N. Mammary and extramammary Paget’s disease. An Bras Dermatol. 2015;90:225–31.CrossRefPubMed
3.
go back to reference Paget J. On disease of the mammary areola preceding cancer of the mammary gland. St Bartholomew Hosp Rev. 1974;10:87–9. Paget J. On disease of the mammary areola preceding cancer of the mammary gland. St Bartholomew Hosp Rev. 1974;10:87–9.
4.
go back to reference Crocker H. Paget’s disease affecting the scrotum and penis. Trans Pathol Soc London. 1889;40:187–91. Crocker H. Paget’s disease affecting the scrotum and penis. Trans Pathol Soc London. 1889;40:187–91.
5.
go back to reference Bagby CM, MacLennan GT. Extramammary Paget’s disease of the penis and scrotum. J Urol. 2009;182:2908–9.CrossRefPubMed Bagby CM, MacLennan GT. Extramammary Paget’s disease of the penis and scrotum. J Urol. 2009;182:2908–9.CrossRefPubMed
6.
go back to reference Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1973–2013), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2017 (based on November 2016 submission). Surveillance, Epidemiology, and End Results (SEER) Program (www.​seer.​cancer.​gov) Research Data (1973–2013), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2017 (based on November 2016 submission).
7.
go back to reference Wright JL, Morgan TM, Lin DW. Primary scrotal cancer: disease characteristics and increasing incidence. Urology. 2011;72:1139–43.CrossRef Wright JL, Morgan TM, Lin DW. Primary scrotal cancer: disease characteristics and increasing incidence. Urology. 2011;72:1139–43.CrossRef
8.
go back to reference Herrel LA, Weiss AG, Goodman M, Johnson TV, Osunkoya AO, Delman KA, et al. Extramammary Paget’s disease in males: survival outcomes in 495 patients. Ann Surg Oncol. 2015;22:1625–30.CrossRefPubMed Herrel LA, Weiss AG, Goodman M, Johnson TV, Osunkoya AO, Delman KA, et al. Extramammary Paget’s disease in males: survival outcomes in 495 patients. Ann Surg Oncol. 2015;22:1625–30.CrossRefPubMed
9.
go back to reference Perrotto J, Abott JJ, Ceilley RI, Ahmed I. The role of immunohistochemistry in discriminating primary from secondary extramammary Paget disease. Am J Dermatopathol. 2010;32:137–43.CrossRefPubMed Perrotto J, Abott JJ, Ceilley RI, Ahmed I. The role of immunohistochemistry in discriminating primary from secondary extramammary Paget disease. Am J Dermatopathol. 2010;32:137–43.CrossRefPubMed
10.
go back to reference Ling H, Hu X, Xu XL, Liu ZB, Shao ZM. Patients with nipple-areola Paget’s disease and underlying invasive breast carcinoma have very poor survival: a matched cohort study. PLoS One. 2013;8:e61455.CrossRefPubMedPubMedCentral Ling H, Hu X, Xu XL, Liu ZB, Shao ZM. Patients with nipple-areola Paget’s disease and underlying invasive breast carcinoma have very poor survival: a matched cohort study. PLoS One. 2013;8:e61455.CrossRefPubMedPubMedCentral
11.
go back to reference Chan JY, Li GKH, Chung JHP, Chow VLY. Extramammary Paget’s disease: 20 years of experience in Chinese population. Int J Surg Oncol. 2012;2012:1–5.CrossRef Chan JY, Li GKH, Chung JHP, Chow VLY. Extramammary Paget’s disease: 20 years of experience in Chinese population. Int J Surg Oncol. 2012;2012:1–5.CrossRef
12.
go back to reference Davis G, Anderson L, Pather S. Extramammary Paget’s disease mimicking localized malignancy on cervical cytology. Diagn Cytopathol. 2016;44:931–4.CrossRefPubMed Davis G, Anderson L, Pather S. Extramammary Paget’s disease mimicking localized malignancy on cervical cytology. Diagn Cytopathol. 2016;44:931–4.CrossRefPubMed
13.
go back to reference Lam C, Funaro D. Extramammary Paget’s disease: summary of current knowledge. Dermatol Clin. 2010;28:807–26.CrossRefPubMed Lam C, Funaro D. Extramammary Paget’s disease: summary of current knowledge. Dermatol Clin. 2010;28:807–26.CrossRefPubMed
14.
go back to reference Karam A, Dorigo O. Increased risk and pattern of secondary malignancies in patients with invasive extrammary Paget disease. Brit J Dermatol. 2014;170:661–71.CrossRef Karam A, Dorigo O. Increased risk and pattern of secondary malignancies in patients with invasive extrammary Paget disease. Brit J Dermatol. 2014;170:661–71.CrossRef
15.
go back to reference Ohara K, Fujisawa Y, Yoshino K, Kiyohara Y, Kadono T, Murata Y, et al. A proposal for a TNM staging system for extramammary Paget disease: retrospective analysis of 301 patients with invasive primary tumors. J Dermatolog Sci. 2016;83:234–9.CrossRef Ohara K, Fujisawa Y, Yoshino K, Kiyohara Y, Kadono T, Murata Y, et al. A proposal for a TNM staging system for extramammary Paget disease: retrospective analysis of 301 patients with invasive primary tumors. J Dermatolog Sci. 2016;83:234–9.CrossRef
16.
go back to reference Ogata D, Kiyohara Y, Yoshikawa S, Tsuchida T. Usefulness of sentinel lymph node iopsy for prognostic prediction in extramammary Paget’s disease. Eur J Dermatol. 2016;26:254–9.PubMed Ogata D, Kiyohara Y, Yoshikawa S, Tsuchida T. Usefulness of sentinel lymph node iopsy for prognostic prediction in extramammary Paget’s disease. Eur J Dermatol. 2016;26:254–9.PubMed
17.
go back to reference Wang Z, Lu M, Dong GQ, Jian YQ, Lin MS, Cai ZK, et al. Penile and scrotal Paget’s disease: 130 Chinese patients with long-term follow-up. BJU Int. 2008;102:485–8.CrossRefPubMed Wang Z, Lu M, Dong GQ, Jian YQ, Lin MS, Cai ZK, et al. Penile and scrotal Paget’s disease: 130 Chinese patients with long-term follow-up. BJU Int. 2008;102:485–8.CrossRefPubMed
18.
go back to reference Wagner G, Sachse MM. Extramammary Paget disease—clinical appearance, pathogenesis, management. J Dtsch Dermatol Ges. 2011;9:448–54.PubMed Wagner G, Sachse MM. Extramammary Paget disease—clinical appearance, pathogenesis, management. J Dtsch Dermatol Ges. 2011;9:448–54.PubMed
19.
go back to reference Kang Z, Zhang Q, Zhang QF, Li X. Hu TT, Xu X, et al. clinical and pathological characteristics of extramammary Paget’s disease: report of 246 Chinese male patients. Int J Clin Exp Pathol. 2015;8:13233–40.PubMedPubMedCentral Kang Z, Zhang Q, Zhang QF, Li X. Hu TT, Xu X, et al. clinical and pathological characteristics of extramammary Paget’s disease: report of 246 Chinese male patients. Int J Clin Exp Pathol. 2015;8:13233–40.PubMedPubMedCentral
20.
go back to reference Fan L, Zhu J, Tao X, Xu C. Intraepithelial extramammary Paget’s disease of the vulva: the clinicopathological characteristics, management, and outcome in a study of 18 female patients. Dermatolog Surg. 2016;42:1142–6.CrossRef Fan L, Zhu J, Tao X, Xu C. Intraepithelial extramammary Paget’s disease of the vulva: the clinicopathological characteristics, management, and outcome in a study of 18 female patients. Dermatolog Surg. 2016;42:1142–6.CrossRef
21.
go back to reference Yang WJ, Kim DS, Im YJ, Cho KS, Rha KJ, Cho NH, et al. Extramammary Paget’s disease of penis and scrotum. Urology. 2005;65(5):972.CrossRefPubMed Yang WJ, Kim DS, Im YJ, Cho KS, Rha KJ, Cho NH, et al. Extramammary Paget’s disease of penis and scrotum. Urology. 2005;65(5):972.CrossRefPubMed
22.
go back to reference Tolia M, Tsoukala N, Sofoudis C, Giagini C, Spyropoulou D, Kardamakis D, et al. Primary extramammary invasive Paget’s vulvar disease: what is the standard, what are the challenges and what is the future for radiotherapy? BMC Cancer. 2016;16:563–71.CrossRefPubMedPubMedCentral Tolia M, Tsoukala N, Sofoudis C, Giagini C, Spyropoulou D, Kardamakis D, et al. Primary extramammary invasive Paget’s vulvar disease: what is the standard, what are the challenges and what is the future for radiotherapy? BMC Cancer. 2016;16:563–71.CrossRefPubMedPubMedCentral
23.
go back to reference Ito Y, Igawa S, Ohishi Y, Uehara J, Yamamoto AI, Iizuka H. Prognostic indicators in 35 patients with extramammary Paget’s disease. Dermatol Surg. 2012;38:1938–44.CrossRefPubMed Ito Y, Igawa S, Ohishi Y, Uehara J, Yamamoto AI, Iizuka H. Prognostic indicators in 35 patients with extramammary Paget’s disease. Dermatol Surg. 2012;38:1938–44.CrossRefPubMed
24.
go back to reference Isrow D, Oregel KZ, Cortes J, Gomez H, Milikowski C, Feun L, et al. Advanced extramammary Paget’s disease of the groin, penis, and scrotum. Clin Med Insights: Oncol. 2014;8:87–90. Isrow D, Oregel KZ, Cortes J, Gomez H, Milikowski C, Feun L, et al. Advanced extramammary Paget’s disease of the groin, penis, and scrotum. Clin Med Insights: Oncol. 2014;8:87–90.
Metadata
Title
Survival analysis of patients with invasive extramammary Paget disease: implications of anatomic sites
Authors
Haijun Yao
Minkai Xie
Shibo Fu
Jianhua Guo
Yubing Peng
Zhikang Cai
Yueqing Jiang
Dachao Zheng
Zhong Wang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4257-1

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine